a Laboratory of Study and Application of DNA Polymorphisms and Immunology, Department of Pathological Sciences , Biological Sciences Center, State University of Londrina, Pr 445 Km 380 Celso Garcia Cid Highway , Londrina , Paraná , Brazil.
b Cancer Hospital of Londrina, Department of Human Pathology , Clinical Analysis and Toxicology, Health Sciences Center, State University of Londrina , Londrina , Parana , Brazil.
Int Rev Immunol. 2018 May 4;37(3):144-150. doi: 10.1080/08830185.2017.1401620. Epub 2017 Dec 19.
Breast cancer represents a complex and heterogeneous disease that comprises distinct disease conditions, histological features, and clinical outcome. Since many years, it has been demonstrated as an association between HER2 amplification and poor prognosis, because its overexpression is associated with an aggressive phenotype of breast tumor cells. A significant proportion of cases have developed resistance to the current therapies available. Consequently, new prognostic markers are urgently needed to identify patients who are at the highest risk for developing metastases. During the past decade, new insights provided valuable knowledge regarding mechanisms underlying the dynamic interplayed between immune cells and tumor progression. It has been shown that the presence of a lymphocytic infiltrate, particularly of regulatory T cells, in cancer tissue, is associated with clinical outcome promoting rather than inhibiting cancer development and progression. It has been also verified that the clinical value of lymphocytic infiltration in breast cancers could be subtype-dependent, including the HER2-enriched subtype. In this context, this work summarizes proposed to discuss the prognostic value of regulatory T cell infiltration in microenvironment of HER2-enriched breast cancer.
乳腺癌是一种复杂且异质性的疾病，包括不同的疾病状况、组织学特征和临床结局。多年来，已经证实 HER2 扩增与预后不良之间存在关联，因为其过度表达与乳腺肿瘤细胞的侵袭性表型相关。很大一部分病例已经对现有治疗方法产生了耐药性。因此，迫切需要新的预后标志物来识别具有最高转移风险的患者。在过去的十年中，新的研究进展为免疫细胞与肿瘤进展之间的动态相互作用提供了有价值的知识。已经表明，肿瘤组织中淋巴细胞浸润的存在，特别是调节性 T 细胞，与促进而不是抑制癌症发展和进展的临床结局相关。也已经证实，淋巴细胞浸润在乳腺癌中的临床价值可能依赖于亚型，包括 HER2 富集亚型。在这种情况下，这项工作总结了讨论 HER2 富集型乳腺癌微环境中调节性 T 细胞浸润的预后价值的建议。
